secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001171843-23-005679
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose signs $7M investment agreement with Hanmi Pharmaceutical; first $3M tranche closed
--------------------------------------------------------------------------------

- First tranche of $3.0M closed at $4.448/share (premium to $4.04 minimum price) for 668,449 shares.
- Second tranche of $4.0M contingent on milestones: CofA, Lonza change orders, positive tuspetinib data by June 30, 2024.
- Investor Rights Agreement: Hanmi gets nomination right (≥10% ownership) and participation right in future offerings.
- Hanmi currently owns ~12.07% of APTO; second tranche capped at 19.99% blocker.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184323005679/0001171843-23-005679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184323005679/f8k_091123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer